, Volume 44, Issue 1, pp 323-325
Date: 25 Jul 2010

Aspirin resistance in hemodialysis patients

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

“Aspirin resistance” is a new concept that is progressively starting to establish itself as a concern in patients with cardiovascular diseases with an estimated incidence of 28% in this population. It is associated with an increase in cardiovascular-related events, acute coronary syndrome and death [1]. The laboratory measurement methods are divided into two major groups: some address platelets aggregation after therapy with aspirin and others measure the ability of aspirin to inhibit platelets TBX biosynthesis. The role of platelets’ function testing in clinical practice is not defined and is still considered more related to the research field [2]. In a recent systematic review, renal impairment was found to be associated with aspirin resistance [1]. This association was described in two studies from the same center with a predominant Asian population [3, 4].

We evaluated the incidence of aspirin resistance in hemodialysis patients using the rapid platelets functional assay for aspirin

This manuscript has been seen and approved by all authors; it is not under consideration for publication elsewhere in a similar form, in any language, except in abstract form.